Homepage

Read about the Oxford Vaccine Centre’s COVID-19 vaccine trial.

Read about Oxford Vaccine Group's Com-Cov vaccine trial investigating different combinations of approved COVID-19 vaccines.

Oxford University researchers release cheap, quick COVID-19 antibody test

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Oxford coronavirus vaccine researcher Katie Ewer inspects samples in the lab

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall. Vaccine 100% effective against severe or critical symptomatic COVID-19. No safety concerns reported

COVID-19: how to tackle vaccine hesitancy among BAME groups

Samantha Vanderslott, Andrew Pollard and Seilesh Kadambari discuss vaccine uptake among Black, Asian and minority ethnic communities in an article for The Conversation.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford University extends COVID-19 vaccine study to children

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

Oxford leads first trial investigating dosing with alternating vaccines

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Take part in a clinical trial – see a list of all the trials we are currently recruiting to.

Child being vaccinated

Non-COVID research statement

The Oxford Vaccine Group will be continuing with some of our non-COVID research, particularly our paediatric studies, during the COVID-19 pandemic. This is because as part of these studies we give babies their routine primary immunisations on behalf of their GPs. This reduces the administrative burden on the NHS, allowing them to free up capacity and prioritise their workload to be focused on doing what is necessary to manage the response to the COVID-19 pandemic. The participants also benefit from having the vaccines in the safety of their homes or a convenient location.

Vaccine Knowledge

The Vaccine Knowledge Project aims to be a source of independent information about vaccines and infectious diseases.

See more

Research

Vaccines are a key component of global health policy and are essential in the defence of the health of young children. Our research focuses on the development and evaluation of new and improved vaccines.

Explore

Events and Training

We are committed to providing high quality education and training, together with research updates for medical professionals and all those involved in the area of vaccines and paediatric and adult infectious diseases.

Learn

Get involved

There are a number of ways in which you can get involved in our research, inform our research and find out more about our work. To find out more about any of these options, follow the link below.

Participate

Latest publications

Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease.
Journal article

Hoggart C. et al, (2021), Eur J Hum Genet
RNA2HLA: HLA-based quality control of RNA-seq datasets
Journal article

Chelysheva I. et al, (2021), Briefings in Bioinformatics
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Journal article

Madhi SA. et al, (2021), N Engl J Med
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
Journal article

Wouters OJ. et al, (2021), Lancet, 397, 1023 - 1034
An analysis of the potential global impact of dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine
Journal article

Aguas R. et al, (2021)

Upcoming events

Online Introduction to Immunisation Training - 20 April 2021

Tuesday, 20 April 2021, 9.30am to 3pm

This training is for general practice nurses and other health professionals who are new to the role of administering and promoting and / or advising about vaccines.

IIC 2021 - The Virtual Edition. Hot Topics In Infection And Immunity In Children

Friday, 02 July 2021

IIC - The ESPID-Oxford Course is a residential training course covering topics in paediatric infection for paediatric infectious diseases trainees and trainers, and for all those who manage children with infections. This will be the 18th edition of the course. After having to cancel last year's IIC, the Organising Committee have decided to hold IIC 2021 as a one-day, intensive virtual event.

Virtual Immunisation Update Training – 13 July 2021

Tuesday, 13 July 2021, 9.30am to 12.30pm

A free immunisation update training for General Practice Nurses and other registered healthcare practitioners who administer/advise about immunisations within the BOB and Frimley ICS. **This is an online training and will be delivered using Microsoft Teams.**

We’ve made a vaccine, now you can make the difference

We’ve heard about how effective vaccines are, but what do we need for them to have the biggest impact on the coronavirus pandemic?

How does herd immunity work?

‘Herd immunity’ or 'herd protection' gives protection to vulnerable people such as newborn babies, elderly people and those who are too sick to be vaccinated.

How to make a vaccine in record time

Vaccines usually take decades to develop – so how is Oxford University's ChAdOx1 nCoV-1 vaccine trial moving so quickly? It comes down to careful planning, extraordinary logistics and a whole lot of help from partners around the world.